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ABSTRACT
Although it is a rare condition, the accurate diagnosis and treatment of Cushing’s disease is important 
due to its higher morbidity and mortality compared to the general population, which is attributed to 
cardiovascular diseases, diabetes mellitus and infections. Screening for hypercortisolism is recom-
mended for patients who present multiple and progressive clinical signs and symptoms, especially 
those who are considered to be more specific to Cushing’s syndrome, abnormal findings relative to 
age (e.g., spinal osteoporosis and high blood pressure in young patients), weight gain associated 
with reduced growth rate in the pediatric population and for those with adrenal incidentalomas. 
Routine screening is not recommended for other groups of patients, such as those with obesity or 
diabetes mellitus. Magnetic resonance imaging (MRI) of the pituitary, the corticotropin-releasing hor-
mone (CRH) test and the high-dose dexamethasone suppression test are the main tests for the differ-
ential diagnosis of ACTH-dependent Cushing’s syndrome. Bilateral and simultaneous petrosal sinus 
sampling is the gold standard method and is performed when the triad of initial tests is inconclusive, 
doubtful or conflicting. The aim of this article is to provide information on the early detection and 
establishment of a proper diagnosis of Cushing’s disease, recommending follow-up of these patients 
at experienced referral centers. Arch Endocrinol Metab. 2016;60(3):267-86
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INTRODUCTION
E ndogenous Cushing’s syndrome can be defined as a condition resulting from prolonged and inappropriate exposure to excessive amounts of cortisol, partial 
loss of the normal counter-regulation of the hypothalamic-pituitary-adrenal axis and 
loss of circadian rhythm in cortisol secretion (1). 
Cushing’s disease (CD) is a rare clinical condition that is due to ACTH-producing 
pituitary adenoma, and it is the most common etiology of endogenous Cushing’s 
syndrome after 6 yrs of age (~70%) (2).
CD has an estimated incidence of 2-3 cases per 1.000.000 inhabitants/year and a 
prevalence of approximately 40 cases per 1.000.000 inhabitants (3), occurring mainly 
in women (3-8: 1) (3,4). It can affect individuals at any age, but it is most prevalent 
in the second and third decades of life and is mostly (~80-90%) caused by pituitary 
tumors with a diameter less than 10 mm (microadenomas) (5-7). 
ACTH-secreting pituitary adenomas are sporadic tumors in the vast majority of 
cases, but they can rarely be part of genetic conditions such as multiple endocrine 
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lial isolated pituitary adenoma (FIPA) (8). Other less 
common etiologies of endogenous Cushing’s syndro-
me include ectopic ACTH secretion (EAS ~10%), adre-
nal adenomas and carcinomas and, more rarely, adrenal 
primary macronodular adrenal hyperplasia (PMAH) or 
primary pigmented nodular adrenal disease (PPNAD) 
(Table 1). In children under 5 years of age, adrenal cau-
ses (ACTH-independent: adrenal adenoma and carci-
noma) are the most common, whereas bilateral adrenal 
hyperplasia due to McCune-Albright syndrome is the 
most common cause in the first year of life. CD is the 
most prevalent etiology (75%) in patients older than 7 
years (2). 
culty in identifying patients with a subtler clinical pic-
ture, which delays the diagnosis of Cushing’s syndrome 
and its etiology. Some studies have shown that this time 
can vary from 2-5 years from the initial consultation 
to the end of investigation (9,22-25), and the longer 
exposure to hypercortisolism has been proved to be an 
independent factor associated with higher mortality in 
patients with Cushing’s syndrome (17). 
Thus, to improve the prognosis of patients with 
Cushing’s syndrome and to enhance the reversibility of 
comorbidities, an early recognition of the disease and 
the reversal of hypercortisolism to eucortisolism are 
essential. Eventually, very severe hypercortisolism may 
present as a medical emergency with very high morta-
lity if not promptly treated. The diagnosis of these pa-
tients must be made expeditiously, and treatment must 
be started immediately (1).
The aim of this article is to provide information 
on the early detection and establishment of a proper 
diagnosis of CD. We recommend monitoring these 
patients in centers with experienced multidisciplinary 
teams (endocrinologists, neurosurgeons, radiologists, 
radio-interventionists) to establish the diagnosis, to 
indicate the best treatment and to conduct follow-ups 
of these patients.
DIAGNOSIS OF ENDOGENOUS CUSHING’S SYNDROME
Who should we investigate for Cushing’s 
syndrome? 
The classic clinical features of Cushing’s syndrome con-
sist of weight gain causing overweight or obesity with 
an abdominal and truncal distribution, fatigue, mens-
trual abnormalities such as oligomenorrhea or ame-
norrhea, reduced libido and/or erectile dysfunction, 
decreased growth rate associated with weight gain in 
children, and psychiatric disturbances including depres-
sion, decreased concentration and memory, irritability 
and insomnia. 
Physical examinations can show a wide variability of 
features related to Cushing’s syndrome, ranging from 
subtle to overt features. In patients who present with 
overt Cushing’s syndrome, we can observe pletho-
ric round face (“moon face”), dorsal hump (“buffalo 
hump”), filled supraclavicular fossa, skin atrophy, acne, 
hirsutism, hair loss, and peripheral edema. In children, 
a short stature, abnormal virilization, pubertal delay or 
pseudo precocious puberty may be observed. Moreo-
ver, there are common comorbidities in clinical prac-
Table 1. Etiologies of endogenous Cushing’s syndrome
Cushing’s syndrome etiology* Prevalence**
ACTH-dependent Cushing’s syndrome 80%
Cushing’s disease 70%
Ectopic ACTH syndrome 10%
Ectopic CRH secretion < 1%
Carcinoma corticotropic Rare
Ectopic CRH/ACTH secretion Rare
ACTH-independent Cushing’s syndrome 20%
Adrenal adenoma 10%
Adrenal carcinoma 5%
Primary macronodular adrenal hyperplasia (PMAH) < 2%
Primary pigmented nodular adrenocortical disease (PPNAD) < 2%
McCune-Albright syndrome Rare
Ectopic cortisol secretion Rare
Cortisol hypersensitivity Rare
* References: 4,49,117,182; ** Prevalence in adult patients. 
Patients with Cushing’s syndrome have a higher 
mortality than the general population (9-21), mainly 
due to the development of cardiovascular disease (is-
chemic heart disease and cerebrovascular disease), dia-
betes mellitus (secondary to hypercortisolism) and in-
fections (due to the state of immunosuppression). 
A meta-analysis showed a standardized mortality 
ratio (SMR) of 2.22 (1.45-3.41; confidence interval 
95%) (15), which varied between studies from 0.98 
(0.44-2.18) (10) to 4.80 (2.79 to 8.27) (15). Howe-
ver, when analyzing the mortality rate in relation to the 
remission of Cushing’s syndrome, there was a higher 
mortality rate in patients with persistent disease compa-
red to those in clinical remission: 5.50 (2.69-11.26) vs. 
1.20 (0.45-3.18), respectively (15). 
Another factor that contributes to the onset and 



















Cushing’s disease diagnosis recommendations
Arch Endocrinol Metab. 2016;60/3
tice, such as hypertension, diabetes mellitus, nephro-
lithiasis, osteopenia or osteoporosis, hypokalemia, and 
unusual fungal infections. However, all of these signs, 
symptoms and morbidities are non-specific, as they 
may be present in metabolic syndrome, severe diabetes 
mellitus, polycystic ovary syndrome, grade III obesi-
ty, depression and chronic alcoholism (26). Thus, it is 
important to look for more specific signs of Cushing’s 
syndrome, such as facial plethora, proximal muscle 
weakness, large (> 1 cm) and reddish/violet skin striae 
and spontaneous ecchymosis in patients presenting 
weight gain (27,28) (Table 2). 
such as small cell lung carcinoma, may have an atypical 
clinical presentation, with a predomination of con-
sumptive state (35%), higher frequency of hypokalemia 
(> 70%), hyperpigmentation, osteopenia/osteoporosis 
and metabolic disorders, such as glucose intolerance 
(29). 
Thus, it is recommended to investigate Cushing’s 
syndrome in patients who have multiple and progressive 
signs and symptoms, especially those considered more 
specific, such as the presence of spinal osteoporosis and 
hypertension, weight gain in children coupled with a 
reduction in growth, and the finding of adrenal inci-
dentalomas. Routine investigation is not otherwise re-
commended for other groups of patients, such as those 
with isolated obesity or hirsutism (27,30,31) (Table 3). 
Table 2. Prevalence of symptoms, signs and morbidities of Cushing’s 
syndrome 
Symptoms, signs and morbidities* Prevalence %
Weight gain or obesity/abdominal obesity 95
Facial plethora 90
Facial fullness 90
Decreased libido/erectile dysfunction 90
Thin skin 85
Menstrual abnormalities/amenorrhea 80





Striae (especially if red or purple and more than 10 mm wide) 70-90
Dorsocervical fat pad/supraclavicular fullness 50-70
Easy bruising 65
Impaired glucose-tolerance/diabetes mellitus 60
Proximal myopathy/weakness 60







Unusual infections/fungal infections 20-50
Hypokalemia 10-70
Acne < 20
Alopecia/female balding < 20
Hyperpigmentation 10
* References: 1,27,49,119,183,184; ** Prevalence in pediatric patients (184).
In contrast, patients suffering from Cushing’s syn-
drome due to EAS, particularly those with malignancies 
Table 3. Recommendations for Cushing’s syndrome screening
Cushing’s syndrome screening*
Presence of multiple and progressive features, especially those more specific 
to Cushing’s**
Unusual features for age (vertebral osteoporosis, arterial hypertension)
Pediatric patients with decreasing growth velocity/short stature and weight 
gain
Adrenal incidentaloma
We do not recommend widespread screening for Cushing’s syndrome in other 
clinical situations (e.g., obesity, diabetes mellitus, hirsutism) without the 
presence of more specific features of hypercortisolism 
* References: 27,30,31; ** Easy bruising, facial plethora, proximal myopathy/weakness, striae 
(especially if red or purple and more than 1 cm wide).
However, several studies have been devoted to in-
vestigating hypercortisolism in groups of patients con-
sidered at risk or in whom the prevalence of Cushing’s 
syndrome may be greater than expected. The at-risk 
conditions often highlighted are secondary hyperten-
sion, in which the prevalence of Cushing’s syndrome 
has been reported to be approximately 0.5-1% of ca-
ses, adrenal incidentalomas (6-9%) and unexplained os-
teoporosis with vertebral fracture (11%) (32,33). 
However, the most studied risk condition is diabe-
tes mellitus, which was found to have a prevalence of 
0.8% (0-3.3%) in a group of 2,381 diabetic patients 
from 12 studies (34-45). Striking Cushing’s features 
have not been described in diabetic patients with an 
HbA1c between 8.4-12.2% associated with hyperten-
sion and overweight/obesity (BMI between 25.4-
34.5 kg/m2). Additionally, other factors such as the 
lack of knowledge of the natural history of this “oc-
cult” Cushing’s syndrome and questions regarding the 
best therapeutic strategy (identification and treatment 
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tus) preclude a recommendation for routine screening 
of Cushing’s syndrome in patients with diabetes melli-
tus (46).
Finally, although there is no indication of the need 
to screen for Cushing’s syndrome in either overweight 
or obesity patients without other suggestive features 
(27-30), one study showed a prevalence of 0.8% of 
Cushing’s syndrome in 783 obese preoperative patients 
undergoing bariatric surgery (47). Interestingly, obese 
patients usually show a normal circadian rhythm of sa-
livary cortisol (48). 
First-line tests 
After clinical suspicion and thorough exhaustive 
exclusion of exogenous sources of glucocorticoids 
of any kind, such as oral, injected, topical or inhaled 
steroids, the diagnosis of Cushing’s syndrome has 
two sequential steps. The first step consists of tests to 
confirm hypercortisolism associated with loss of normal 
circadian rhythm of cortisol secretion and the relative 
autonomy of cortisol production, independent of the 
etiology of Cushing’s syndrome. It is noteworthy that 
at least two distinct methods must be abnormal to 
diagnose Cushing’s syndrome. Altered findings from 
only one method may be present in cases of pseudo-
Cushing’s. 
In a subsequent step, which is usually performed 
at referral centers, the establishment of the differen-
tial diagnosis of ACTH-dependent or independent 
Cushing’s syndrome should be conducted (49). 
The diagnosis of Cushing’s syndrome is very much 
dependent on cortisol tests, which vary substantially 
depending on the utilized assay. Therefore, clinicians 
involved in this diagnosis should be aware of their ins-
titutional assays before adhering to the strict cut-offs 
suggested by the literature.
Low-dose dexamethasone suppression test 
The low-dose dexamethasone suppression test 
(LDT) constitutes one of the main methods used for 
screening, and it evaluates for a lack of negative feedback 
of cortisol on the hypothalamic-pituitary-adrenal axis. 
This test should be performed after an overnight 
oral intake (between 11:00 pm and 12:00 am) of 
1 mg dexamethasone, and blood collection for 
measurement of serum cortisol should occur in the 
subsequent morning between 8:00 am and 9:00 am. 
Cortisol values above 1.8 μg/dL (50 nmol/L) are 
considered abnormal, with a sensitivity higher than 
95% and an 80% specificity (27) (Table 4). 
Previously, the cutoff value was higher than 5 μg/dL 
(140 nmol/L), which is still currently used by some au-
thors in some specific clinical situations (e.g., adrenal inci-
dentalomas). However, although this criterion increases 
the specificity of the method (50), the present approach 
is more adequate and sensitive because it is known that 
18% of patients with Cushing’s syndrome have sup-
pressed values below 5 μg/dL, and up to 8% of patients 
with Cushing’s syndrome have suppressed serum cortisol 
below 1.8 μg/dL with 1 mg dexamethasone (51). 
Table 4. Laboratory methods for Cushing’s syndrome diagnosis
Method Reference value Sensitivity % Specificity %
First-line methods
Low-dose dexamethasone suppression test - 1 mg overnight (serum cortisol) (27) > 1.8 µg/dL > 95 80
Longer low-dose dexamethasone suppression test - 2 mg/day for 48 h – 0.5 mg 6/6 h (serum 
cortisol) (68)*
> 1.8 µg/dL 92-100 92-100
Late night salivary cortisol (µg/dL or ng/dL or mmol/L) (56) > 2X ULNR 88-100 82-100
Urinary free cortisol 24 h (µg/24 h) (68) > 3-4X ULNR 90-98 45-95
Other methods (second-line)
Late-night serum cortisol (patient awake) (78) > 7.5 µg/dL 96 100
Ovine CRH after longer low-dose dexamethasone suppression test (serum cortisol) (81-84) > 1.4 µg/dL (15’) < 100 < 100
Human CRH test (plasma ACTH, pg/mL; serum cortisol, µg/dL) (86) Peak > 54 pg/mL 
and > 12 µg/dL 
(baseline) 
91.3 98.2
Desmopressin test (plasma ACTH, pg/mL; serum cortisol, µg/dL) (90) ∆ > 18 pg/mL and > 
12 µg/dL (baseline)
86.6-100 92.8
∆: delta: peak less baseline value; ULNR: upper limit of normal range; * Meta-analysis showed a similar or lower accuracy than that of the low-dose dexamethasone suppression test (1 mg overnight) 
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False positives can occur in states of hyperactiva-
tion of the hypothalamic-pituitary adrenal axis (pseu-
do-Cushing’s state, such as depression and alcoholism) 
and in conditions increasing cortisol-binding globulin 
(CBG) such as estrogen treatment, which accounts for 
up to 50% of the false positives and requires interrup-
tion for at least 6 weeks before the test. Other false 
positive results may occur due to pregnancy, mitotane 
use, malabsorption of medication or conditions that 
increase the metabolism of dexamethasone due to acti-
vation of the enzyme CYP3A4 (phenytoin, phenobar-
bital, rifampin, carbamazepine, pioglitazone, topirama-
te etc.) (Table 5). False negatives can occur in “mild” 
Cushing’s syndrome and with the use of drugs that re-
duce the action of the enzyme CYP3A4 (fluoxetine, ci-
metidine, itraconazole, ritonavir, diltiazem, and amio-
darone, among others). Moreover, even drugs that are 
not traditionally known for changes in the metabolism 
of dexamethasone may do so as a result of an interac-
tion with other drugs. A complete list of medications 
can be found on the following site: http://medicine.
iupui.edu/flockhart/table.htm. 
Likewise, a recent study assessing the influence of 
the use of several concomitant medications on oCRH 
stimulation after longer low-dose dexamethasone sup-
pression tests confirmed a low accuracy of the method 
in patients receiving those medications (52). 
As a result, serum dexamethasone concentrations 
(1 mg overnight: > 140-220 ng/mL) (27,30) that are 
measured at the same time as serum cortisol can rule 
out possible confounding factors, increasing the reli-
ability of the method. However, the measurement of 
dexamethasone is rarely available in our country. 
There is no evidence that the use of higher doses of 
overnight dexamethasone (1.5 or 2 mg) increases the 
accuracy of the method. Furthermore, the same pro-
cedure used in the adult population has been applied 
to pediatric populations, with the only change being a 
dose adjustment (15-20 µg/kg) for patients weighing 
less than 40 kg (2,53). 
Alternatively, some authors prefer a low-dose dexa-
methasone test using fractionated doses rather than 
1 mg overnight to increase the specificity of the meth-
od in states of hyperactivation of the hypothalamic-pi-
tuitary-adrenal axis, such as depression, alcoholism or 
even uncontrolled diabetes mellitus. In such cases, 0.5 
mg of dexamethasone is administered every 6 hours for 
two days (8 doses), most commonly beginning with the 
first dose on the first day at 9:00 am and the last dose 
Table 5. Drugs that may interfere with the evaluation of dexamethasone 
suppression tests
Drugs that accelerate dexamethasone metabolism – induction of CYP 









Drugs that impair dexamethasone metabolism – inhibition of CYP 3A4 









LDT: low-dose dexamethasone suppression test. Reference: 27. More complete data available 
on the following site: http://medicine.iupui.edu/flockhart/table.htm.
occurring at 3:00 am on the last day (6 hours before 
blood collection at 9:00 am) or with the first dose at 
lunch (12:00 pm) on the first day and the last dose at 
6:00 am on the last day (two hours before cortisol col-
lection). Conceived by Liddle in the 1960s and using 
cortisol metabolite in the urine (17OHCS), the same 
criterion of a serum cortisol response > 1.8 µg/dL is 
currently adopted. The non-fractionated 1 mg test is 
preferable to the 48-h fractionated one because the 
latter is labor intensive and more error-prone and has 
shown a diagnostic accuracy slightly lower than that of 
the overnight test in an important meta-analysis (54). 
Thus, rather than choosing the form of dexametha-
sone administration, it is important to emphasize that 
at this stage of diagnosis, a greater sensitivity of the me-
thods should be prioritized and, especially in cases of 
mild Cushing’s, the complementarity and agreement 
of different methods will confirm the diagnosis, as just 
one abnormal result does not confirm the diagnosis of 
the syndrome. 
Late-night salivary cortisol 
Late-night salivary cortisol is an important method 
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It should be ordered whenever available, especially in 
centers with an established methodology and cutoff 
values that have been  studied in different populations 
(normal, obese/pseudo-Cushing’s and Cushing’s syn-
drome), with a sensitivity of 88-100% and specificity of 
82-100% (55,56) for adults, and of 95.2 and 100%, res-
pectively, for children (53). 
 An above normal value on this test reflects the 
lack of a normal circadian rhythm of cortisol secretion, 
which is considered one of the first events to occur in 
Cushing’s syndrome. Therefore, some authors have ad-
vocated using this test as a first method of screening 
(33,56-58). 
In a study of 11 cases of mild Cushing’s that had a 
difficult diagnosis, the measurement of late-night sali-
vary cortisol proved to be persistently altered in most 
patients, while most of the urinary cortisol samples re-
mained within the normal range (59). Another recent 
study found a higher diagnostic accuracy of nocturnal 
salivary cortisol when compared to urinary cortisol in 
52 patients with Cushing’s syndrome (60). 
Salivary cortisol is an analysis method that assesses 
free cortisol, in dynamic equilibrium with serum 
cortisol, reflecting a percentage of total serum cortisol 
(65%), and it is not influenced by saliva flow (61). 
There are several advantages of this method, such as 
the non-invasiveness of its collection and the sample 
stability at room temperature (either one week at room 
temperature or a few weeks if refrigerated). 
Salivary cortisol can be collected in two ways: pas-
sive collection (best for small children) or through a 
commercial collector (Salivette®) between 11:00 pm 
and 12:00 am. It is recommended to collect at least two 
samples on consecutive or alternate days (62). Salivary 
cortisol concentrations are commonly determined by 
radioimmunoassay, ELISA, and automated electroche-
miluminescence (62,63); more recently, liquid chro-
matography/mass spectrometry has also been utilized 
(30,64-66). 
It must be emphasized that a significant conversion 
of cortisol to cortisone occurs in the salivary glands by 
the action of 11β-hydroxysteroid dehydrogenase II en-
zyme (11β-HSD2), leading to a higher concentration 
of cortisone than cortisol in the saliva. This fact could 
explain the finding of the same (92%) or even lower 
(74.5%) sensitivity with equal specificity (90-92%) 
of salivary cortisol by liquid chromatography/mass 
spectrometry (LC-MS/MS) in diagnosing Cushing’s 
syndrome (64-65) compared with the sensitivity and 
specificity of conventional immunoassays using anticor-
tisol antibodies, showing cross-reactivity with cortisone 
(55,67). The use of LC-MS/MS can be particularly 
useful in cases of saliva contamination with synthetic 
steroids (67). 
Because different studies have used different cutoff 
values  with different methods, there is no cutoff value 
for salivary cortisol that can be widely recommended, 
unlike the interpretation of serum cortisol after low-do-
se dexamethasone. Late-night salivary cortisol values 
more than twice the upper limit have been found to 
increase the specificity of the method in diagnosing 
hypercortisolism (67). A review found a mean late-ni-
ght salivary cortisol level of 250 ± 104 ng/dL (130-
415 ng/dL) in patients with Cushing’s syndrome (68). 
As with any method, false negatives and most es-
pecially false positives can occur in individuals with an 
altered sleep-wake cycle, psychiatric disorders, uncon-
trolled diabetes mellitus, and oral/gum disease (blood 
contamination) and in the elderly (27,37,55); addi-
tionally, extremely high results can be due to conta-
mination with corticosteroids in skin creams (57). In 
addition, it is recommended not to smoke 24 h before 
collection due to glycyrrhizic acid (derived from lico-
rice), which inhibits the 11β-HSD2 salivary enzyme. 
Finally, there have been studies on using morning 
salivary cortisol levels after an overnight ingestion of 
1 mg dexamethasone rather than a traditional serum 
cortisol test (37,69,70). Given the ease, convenience 
and noninvasive method of its collection, this may be 
an alternative to initial screening as it easily compri-
ses two screening methods (late-night salivary cortisol 
from the previous night and subsequent salivary corti-
sol after dexamethasone suppression). However, to im-
plement a method of salivary cortisol after dexametha-
sone suppression, the cross-reactivity of dexamethasone 
and salivary cortisol should be first ruled out for the 
chosen assay.
24-h urinary cortisol
The measurement of free cortisol in 24-h urine samples 
(24-h UFC) as well as serum cortisol suppression tests 
after low-dose dexamethasone are the traditional diag-
nostic methods used for the diagnosis and monitoring 
of patients with Cushing’s syndrome. The 24-h UFC 
measurement reflects the integrated daily production of 
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At least two samples of 24-h UFC, consecutive or 
alternate, must be requested to exclude false negatives 
due to variations in cortisol secretion, and 24-h UFC 
should always be evaluated together with a 24-h creati-
nine ratio to confirm the adequacy of the sample. 
One study found at least one normal sample of 24-h 
UFC out of four samples in 11% of patients with hyper-
cortisolism (71), and other recent studies have shown 
a variation of 31-52% in urinary cortisol concentrations 
in 3-4 samples obtained from the same patients at diag-
nosis (60,72). Each sample must be collected for 24 h, 
discarding the first urine sample and including the first 
urine of the morning the subsequent day. The sample 
must be kept refrigerated until it is delivered to the 
laboratory. 
False positives can occur in states of pseudo-
Cushing’s, such as depression, alcoholism, obesity, 
pregnancy, and polyuria (example: patients with dia-
betes insipidus), by the interference of certain drugs 
(carbamazepine, fenofibrate, digoxin, some synthetic 
corticosteroids) and other substances that inhibit the 
11β-HSD2 enzyme (licorice, carbenoxolone). How-
ever, in these cases, the 24-h UFC concentrations are 
usually less than 1.5-2 times above the upper limit 
of the method. False negatives may occur in patients 
with renal insufficiency (creatinine clearance less than 
60 mL/minute), mainly due to an inadequate collec-
tion of urine (27). 
In addition, slightly elevated or normal samples also 
occur in mild Cushing’s syndrome, adrenal incidentalo-
mas, cyclic Cushing’s syndrome and ACTH-secreting 
macroadenomas. Currently, considering the data from 
the three first-line methods, urinary cortisol has been 
less valued than the others as a screening test for the di-
agnosis of Cushing’s syndrome (67,73). Likely, a slight 
increase in cortisol production in the circadian nadir 
may not be detected as an increase in 24-h UFC. Nev-
ertheless, it remains an important method when used in 
combination with other diagnostic methods, although 
it is especially valued and more specific when the ob-
served result is 3-4 times greater than the upper limit 
of the method. 
It is noteworthy to mention that the same reference 
values for adults can be used in children over 45 kg, 
with a sensitivity of approximately 89% (74,75). 
In general, 24-h UFC does not experience inter-
ference from conditions that increase corticosteroid-
binding globulin (CBG). There are several methods 
used to measure 24-h UFC, in particular immunoas-
says with upper limits of approximately 90-120 µg/24 h. 
Recently, and similarly to other steroids, more specific 
methods have been used, such as high performance liq-
uid chromatography (HPLC) and mass spectrometry, 
with upper limits typically ranging from approximately 
40 to 60 µg/24 h. One study showed differences in the 
value of 24-h UFC in relation to gender, with slightly 
higher values in women (76), while other studies have 
found the opposite (77). 
Additional tests or second-line tests
Second-line tests are indicated when diagnostic uncer-
tainty persists after the completion of first-line tests. 
This is particularly true for cases of mild Cushing’s syn-
drome in which the complementarity and correlation of 
different methods is necessary for a confirmed diagnosis 
of hypercortisolism (54).
Late-night serum cortisol 
Although it is an older method and has the same ra-
tionale as the nocturnal salivary cortisol test, late-night 
serum cortisol is considered a second-line examination 
because it requires the hospitalization of the patient for 
sample collection at least 48 hours after admission, bet-
ween 11:00 pm and 12:00 am. 
Several studies have analyzed this method, but with 
different control groups, different collection methods 
(patient asleep or awake) and with different cutoff val-
ues. The most commonly used cutoff value in the lit-
erature originates from a 1998 study indicating that a 
cortisol value higher than 7.5 µg/dL is suggestive of 
Cushing’s syndrome (patient at rest, but awake) with 
96% sensitivity and 100% specificity (78). 
A previous study performed collection in sleeping 
patients (with previously installed venous access) 
and found a cortisol value higher than 1.8 µg/dL as 
suggestive of Cushing’s syndrome with 100% sensitivity 
(79). However, because collection is not always easy in 
a sleeping patient and the cutoff was very low, other 
studies have not replicated these data with enough 
specificity (80). Due to the increased availability and 
the advantages of late-night salivary cortisol over late-
night serum cortisol, the latter is currently seldom used. 
Alternatively, and with the same goal, serum cortisol 
at 4:00 pm has also been analyzed. However, there is 
a substantial overlap in cortisol values between patients 
with or without Cushing’s syndrome, preventing an ac-
curate interpretation of the serum cortisol collected at 
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Ovine CRH stimulation after longer low-dose 
dexamethasone suppression test
Also known as the Yanovski test, the ovine CRH test 
was published in 1993 (81). It is still considered by 
some authors as the best method for the differential 
diagnosis between Cushing’s syndrome and states of 
pseudo-Cushing’s. It is performed with 0.5 mg dexa-
methasone suppression for two days (8 doses) with the 
last dose at 6:00 am. Then, after two hours, there is 
an IV infusion of 1 µg/kg or 100 µg of ovine CRH 
(oCRH). A serum cortisol value higher than 1.4 µg/dL 
(absolute value) after 15 minutes is considered positive 
and suggestive of Cushing’s syndrome. In the original 
publication, this method showed 100% accuracy, an ex-
ceptional result, although this has not been reproduced 
by others (52,82-84). Furthermore, due to the high 
cost and unavailability of ovine CRH, its use is currently 
limited. Therefore, we do not recommend this poorly 
characterized, expensive and complex test.
Human CRH test
Traditionally used for the differential diagnosis of 
ACTH-dependent Cushing’s syndrome (85), the hu-
man CRH (hCRH) test was studied in 2009 to differen-
tiate Cushing’s syndrome from states of pseudo-Cush-
ing’s (86). Using statistical analysis to obtain maximum 
accuracy, the best criterion found has been a serum cor-
tisol value higher than 12 µg/dL at baseline (absolute 
value, mean time -15 and 0 min) and peak ACTH high-
er than 54 pg/mL (absolute value) after a 100 µg IV 
infusion of hCRH, with a sensitivity of 91.3% and speci-
ficity of 98.2% for CD, which was better than both first-
line methods and nocturnal serum cortisol. Howe ver, 
as with oCRH, due to the high cost and unavailability 
of the product in Brazil, its use is still currently limited.
Desmopressin test
Desmopressin has been used for the differential diag-
nosis of ACTH-dependent Cushing’s syndrome since 
1993 (87). Moreover, it has also been studied with the 
aim of differentiating Cushing’s syndrome from states 
of pseudo-Cushing’s (88). 
However, as of 2000, the desmopressin test (10 µg 
IV) showed no significant accuracy in ruling out pseu-
do-Cushing’s states due to a frequent response (> 50%) 
in normal subjects when using percentage increases in 
both ACTH and cortisol as the response criteria (89). 
In 2007, a study showed equal accuracy between the 
desmopressin and Yanovski test, but it used the criteria 
of an ACTH ∆ > 27 pg/mL after desmopressin (84 vs. 
85%, respectively) (50). 
Similar to the hCRH test previously reported (86), 
the same group published a new reassessment of the 
desmopressin test after an intensive statistical analysis 
in 2010, finding new response criteria: serum cortisol 
higher than 12 µg/dL at baseline (mean between -15 
and 0 min) and an ACTH increase of > 18 pg/mL 
(peak until 30 min minus the baseline value). Using this 
criteria, a sensitivity of 86.6-100% and a specificity of 
92.8% was found, higher than that of the previous cri-
teria of ∆ > 27 pg/mL and again better than the use of 
increase-percentage values in both ACTH and cortisol. 
Importantly, this study provided a differential diagnosis 
of mild Cushing’s syndrome vs. pseudo-Cushing’s, pro-
viding an advantage when compared to first-line me-
thods and the late-night serum cortisol test (90). 
In 2011, one study compared the hCRH with the 
desmopressin test using the new criteria and verified 
the identical and excellent performance of both tests in 
the differential diagnosis of ACTH-dependent Cush-
ing’s syndrome and states of pseudo-Cushing’s, with 
a 96.6% sensitivity and 100% specificity for both tests 
(91), results even better than both first-line methods 
and nocturnal serum cortisol. 
Finally, a recent study in patients with CD (n = 68) 
and patients with pseudo-Cushing’s (n = 56) demon-
strated by ROC curves the use of a peak ACTH value of 
71.8 pg/mL after desmopressin, showing a 94.6% spec-
ificity, 90.8% sensitivity, 89.8% negative predictive value 
(NPV) and 95.3% positive predictive value (PPV) for 
the diagnosis of CD. In the same study, an increase of 
ACTH equal to or greater than 37 pg/mL after desmo-
pressin showed 88% sensitivity, 96.4% specificity, 87% 
NPV and 95.3% PPV also for the diagnosis of CD (92). 
Therefore, the desmopressin test seems to be a 
good method for the differential diagnosis of ACTH-
dependent Cushing’s syndrome and states of pseudo-
Cushing’s. Due to the greater availability and lower 
cost of desmopressin, it should be further studied. 
Special situations 
Pregnancy
The diagnosis of Cushing’s syndrome, though rarely 
concomitant with pregnancy (93,94), presents unique 
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logy, accounting for 46% of Cushing’s syndrome cases 
in pregnancy (93,94). It is also occasionally a cause of 
pseudo-Cushing’s (95,96). 
False positive results commonly occur with low-dose 
dexamethasone suppression tests in pregnancy due to a 
secondary CBG increase related to estrogen levels during 
pregnancy as well as the attenuation of axis suppression 
in pregnancy (93,94). Regarding 24-h UFC, although 
not influenced by CBG increase, an important physio-
logical increase in urinary cortisol concentrations in the 
second and third trimesters has been shown, which can 
reach up to three times the upper limit of the method 
(97). Thus, only concentrations higher than 3-4 times 
the upper limit of the method can be useful for diagnosis. 
Typically, the circadian rhythm of cortisol secretion 
is maintained during gestation and should theoretically 
be explored for diagnosis. However, there are no speci-
fic studies that define cutoff values for late-night serum 
cortisol during pregnancy, and there are only two stu-
dies that assess late-night salivary cortisol with a small 
group of pregnant women (98,99). Therefore, studies 
are needed to validate this method in pregnant women. 
There are also no specific data on the use of CRH or 
desmopressin in this population. 
Epilepsy
In the subgroup of individuals with epilepsy, the best 
methods are late-night salivary/serum cortisol and 
24-h UFC. Cortisol suppression tests with low-dose 
dexamethasone should be avoided due to an interfe-
rence with dexamethasone metabolism by antiepileptic 
medications such as phenytoin, phenobarbital and car-
bamazepine, among others. In addition, carbamazepi-
ne metabolites can cause false positives results in 24-h 
UFC when analyzed by HPLC. One way to improve 
this accuracy is a concomitant dosage of serum dexa-
methasone, which should be higher than 140-220 ng/dL 
after 1 mg overnight intake (27,30), although its avai-
lability is limited.
Renal insufficiency
Traditionally, 24-h UFC should not be used for patients 
with renal insufficiency due to their decreased renal ex-
cretion with a reduced creatinine clearance of less than 
60 ml/min. In this subgroup of patients, late-night sali-
vary cortisol or late-night serum cortisol should be used 
instead (100). A low-dose dexamethasone suppression 
test can be used with the same cutoff value of 1.8 µg/dL. 
However, with progressed reduction in creatinine clear-
ance, there is a decreased excretion of dexamethasone, 
which may then lead to false negative results. 
Cyclical Cushing’s syndrome
The assessment of cyclical Cushing’s syndrome is a ma-
jor diagnostic and therapeutic challenge. This challenge 
is in part due to its low frequency, at approximately 15% 
of cases (101), but is also due to a great variability in the 
duration and interval between cycles, which can vary 
from days to years (101,102). Importantly, diagnostic 
and etiological research should only be carried out in 
the presence of active hypercortisolism because tests 
are negative during the inactive phase of the disease. 
Because of this variability, several cortisol samples are 
usually necessary (24-h UFC or nocturnal salivary cor-
tisol) to characterize the cycle, and late-night salivary 
cortisol is, therefore, the most practical (103). 
The low-dose dexamethasone suppression test is 
not considered the best method, as it can have false 
negative results when performed in between cycles. 
Recently, the utility of capillary (hair) cortisol has 
been evaluated with the goal of establishing a tempo-
ral characterization of the cortisol secretion in cyclic 
Cushing’s syndrome (104). 
Adrenal incidentaloma
The screening of Cushing’s syndrome is formally in-
dicated in the subgroup of patients with adrenal in-
cidentaloma because 5.3-9.2% of the patients present 
subclinical Cushing’s syndrome (105,106). The recom-
mended initial examination is a low-dose dexametha-
sone suppression test, using a cutoff of 1.8 µg/dL to 
optimize the sensitivity of the method (27). Other val-
ues, such as 5 µg/dL (107,108) or 3 µg/dL in an over-
night 3 mg test, increase the specificity of the method 
but reduce its sensitivity (109). 
As an alternative, late-night salivary cortisol can be 
used, but it has shown less sensitivity when compared 
to the low-dose dexamethasone suppression test in this 
subgroup of patients (57,110-113). Finally, with re-
gard to first-line methods, 24-h UFC is the method 
with the highest number of false negative results, as it 
is diagnostic only when the disease is overt. Other test 
results may be useful, such as measurements of ACTH 
and DHEAS, which may be suppressed in these cases, 
as well as an attenuated response of ACTH and cortisol 
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Figure 1 shows a flowchart for the diagnosis of 
Cushing’s syndrome.
DIFFERENTIAL DIAGNOSIS OF ACTH-DEPENDENT 
CUSHING’S SYNDROME
After a laboratorial confirmation of endogenous 
Cushing’s syndrome, the subsequent diagnostic approa-
ch is to classify the syndrome according to the plas-
ma ACTH levels: ACTH-dependent (ACTH higher 
than 20 pg/mL: CD vs. EAS) or ACTH-independent 
(ACTH less than 10 pg/mL: adenomas, carcinomas, or 
adrenal hyperplasia) Cushing’s syndrome. Due to the 
non-regular secretion of ACTH, it is recommended to 
perform at least two measurements on different days to 
confirm the condition (49,114). ACTH values  in the 
range of 10-20 pg/mL are considered indeterminate, 
and new samples must be ordered. 
Due to the scope of this recommendation manus-
cript, we will only address the differential diagnosis be-
tween CD and EAS. 
Cushing’s syndrome supposed
- Exclude exogenous glucocorticoid source
Perform ≥ 1 first line method
- LDT - 1 mg overnight
- Late-night salivary cortisol (≥ 2 samples)
- UFC (≥ 2 samples)
LOW ABNORMAL OR DOUBTFUL exams
- Cushing’s syndrome NOT CONFIRMED/SUSPECTED
- Repeat first line methods and/or consider additional methods:
- Desmopressin test




- Monitoring, review and treatment of morbidities
Cushing’s syndrome CONFIRMED
- Measure ACTH (≥ 1 Sample)
NORMAL exams
- Cushing’s syndrome EXCLUDED
- Consider cyclic: monitoring and review if necessary
VERY ABNORMAL exams
- Cushing’s syndrome CONFIRMED
- Measure ACTH (≥ 1 Sample)
LDT: low-dose dexamethasone suppression test with 1 mg overnight; UFC: urinary free cortisol; oCRH: ovine; hCRH: human CRH; LLDT: longer low-dose dexamethasone suppression 
test (2 mg/day for 48 h).
Figure 1. Flowchart of Cushing’s syndrome diagnosis.
CD represents 86-93% of the cases of ACTH-de-
pendent Cushing’s syndrome (115-117). Because of 
the high pretest probability of a CD diagnosis, 90% 
in women and 70% in men, diagnostic methods must 
ideally show an accuracy higher than 80-90%. 
Many methods are used for this purpose, although 
a triad is usually initially chosen: magnetic resonance 
imaging (MRI) of the pituitary, a CRH test, and a 
high-dose dexamethasone suppression test (HDDST). 
Whenever these three methods are not conclusive, 
bilateral and simultaneous inferior petrosal sinus sampling 
(BIPSS) remains the gold standard procedure for the 
differential diagnosis of CD and EAS (49,114,118-123).
Pituitary MRI
Pituitary MRI is usually the first exam to be ordered 
and remains the most important in defining the need 
for BIPSS. Due to the diagnostic difficulties and the 
necessity of sensitive methods, computerized tomo-
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a full cranium/brain MRI is considered not ideal for 
providing slices that are thin enough and focused to the 
sellar region. 
CD is caused by pituitary microadenomas (less than 
10 mm) in 80-90% of such cases (5-7). 
Conventional MRI spin echoes can present pitfalls 
such as artifacts (e.g., hyposignals of the pituitary pa-
renchyma adjacent to the bony septum insertion of the 
sphenoid sinus in the sella floor) and the possibility of 
contrast uptake in the pituitary tumor. Therefore, the 
sensitivity of the conventional MRI spin echo is 50-60% 
(124), even for procedures using dynamic MRI. 
In cases in which an expansive pituitary macroade-
noma (greater than 10 mm) is found, the diagnosis of 
CD is virtually confirmed. This presumed confirmation 
is important because this subset of patients may have a 
poorer response to a CRH test (125) and less suppres-
sion in the HDDST (5,7,125,126). 
Currently, a maximum diameter of more than 6 mm 
is suggestive of CD etiology (22,49,118,121,123), es-
pecially for patients who respond to a CRH test and 
present cortisol suppression in the HDDST. 
Other secondary findings from the MRI, although 
nonspecific, may also be helpful in diagnosing a 
microadenoma, such as deviations from the pituitary 
stalk, commonly to the opposite side of an expansive 
lesion, bulging of sella turcica or upper contours of the 
pituitary parenchyma, hyperintensity in the T2-weighted 
sequence by small intra-tumor cystic degeneration, and 
adjacent invasion of a cavernous sinus. 
Thus, a patient with concordant tests suggestive of 
CD, a pituitary image slightly smaller than 6 mm that 
is also coupled with the above-mentioned suggestive 
MRI findings, is usually sufficient to establish the diag-
nosis of a central source of ACTH. Finally, for those 
who have lesions smaller than 10 mm with or without 
secondary findings on the MRI but who show negative 
or inconclusive results on dynamic testing of ACTH 
and cortisol, BIPSS is recommended to establish or ne-
gate the diagnosis of CD. 
To increase the pituitary MRI accuracy, other te-
chniques have been sought for diagnostic improvement: 
spoiled gradient recalled acquisition (SPGR), which in-
creases sensitivity through thinner slices (1 mm) and 
provides a more focused image resulting in a better soft 
tissue definition (124,127-129), has been tested, al-
though it also increases the amount of artifacts and fal-
se positives. Additionally, 3-Tesla MRI (130-132) and 
other techniques have also been studied. More studies 
and a greater availability of these methods are needed 
to confirm their contribution to the diagnosis of CD. 
CRH test 
A CRH test is the best non-invasive dynamic test to 
differentiate CD from EAS. First identified in the 1980s 
(133), it has been extensively studied in this context. 
Most cases of CD respond significantly to CRH (86-
93%) (1), whereas EAS patients respond in 5.5-8.2% of 
cases (115,134). The enhanced responses to CRH in 
CD are as much due to deranged feedback as they are 
to an over-expression of CRH receptors.
The test is performed using ovine CRH (oCRH) 
or human CRH (hCRH). OCRH is the most studied 
peptide, as it has a more powerful and prolonged sti-
mulus. Most commonly, a positive response is defined 
as an increase compared to baseline values (peak minus 
baseline) that is higher than 20% for cortisol and higher 
than 35% for ACTH with oCRH (135). For evalua-
tions using hCRH, a positive response is considered for 
increases greater than 14% for cortisol and greater than 
105% for ACTH (85,86). 
The study that defined the cutoff values for the 
hCRH test (higher than 14% for cortisol and higher 
than 105% for ACTH)  found a 70% and 85% sensitivity 
for ACTH and cortisol, respectively, and 100% specific-
ity for each hormone (85). 
The test is performed with an IV infusion of 1 µg/kg 
or 100 µg of ovine or human CRH without prior dexa-
methasone suppression. The rationale for the test is 
based on the overexpression of the CRH receptor sub-
type 1 (CRHR1) in corticotropic tumors when com-
pared to both normal pituitary tissue (136,137) and 
tumors causing EAS (138). As mentioned previously, 
due to the high cost and unavailability of CRH, the 
routine use of this method is limited.
High-dose dexamethasone suppression test 
Of the initial triad, the HDDST is advantageous due to 
its availability and cost. However, it is the most questio-
ned method in the literature due to its limited accuracy 
in differentiating between CD and EAS (49,139). 
The rationale behind this method is the preservation 
of negative feedback at higher doses of glucocorticos-
teroids in patients with corticotropic tumors. However, 
25-30% of patients with EAS can also show the same 
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The HDDST is an old method (> 50 years) and 
was initially designed to measure cortisol metabolites 
in 24-h urine (17-OHCS) (141). Currently, it is 
performed through the measurement of serum cortisol 
between 8:00 am and 9:00 am before and after a high-
dose (8 mg) oral night intake of dexamethasone and is 
considered suggestive of CD when a reduction of more 
than 50% is observed compared to the baseline value. 
In brief, it can be performed with two protocols: 2 mg 
of dexamethasone every 6 hours for two days (8 doses – 
the classic method) or a simplified method with intake of 
a single 8 mg overnight dose. The sensitivity and specifi-
city of this method varies greatly due to the different pro-
tocols of dexamethasone administration used and to the 
different modes of cortisol analysis (urinary or serum). 
To increase the specificity of the method, a more 
stringent criterion has been proposed for CD diag-
nosis, namely a greater than 80% cortisol suppression 
(140,142). Using this criterion and the single intake 
of 8 mg overnight, one study showed 100% specificity 
in a small group (n = 7) of patients with EAS, in which 
28.6% of the patients suppressed cortisol at a level high-
er than 50%. However, in this same study, only 56% of 
the 39 patients with CD showed greater than 80% sup-
pression, for a total accuracy of only 63% (140). 
Finally, there has been an attempt to combine CRH 
response and the HDDST to increase the specificity of 
CD diagnoses. However, even the combination of the 
methods and the use of the most appropriate cutoff val-
ues  has not provided enough accuracy to preclude the 
need for BIPSS in several cases. 
Bilateral and simultaneous inferior petrosal sinus 
sampling 
This method remains the gold standard for the differen-
tial diagnosis of ACTH-dependent Cushing’s syndrome 
with an accuracy of approximately 90-98% (143-145). 
Bilateral and simultaneous inferior petrosal sinus sam-
pling is indicated in cases where the triad of initial tests 
is inconclusive or discordant (49,118-123) (Figure 2). 
Cushing’s syndrome CONFIRMED
- Measure plasma ACTH (≥ 1 sample)
ACTH < 10 pg/mL
ACTH-independent Cushing’s
BIPSS
Imaging and laboratorial methods








- Anatomic imaging methods: USG/CT/MRI
- Functional imaging methods: OctreoScan®/PET-CT
Sellar MRI
- Lesion with > 6 mm of diameter
CRH test (ovine or human)
HDDST
- Consider cutoff of > 80% for Fs supression
ACTH 10-20 pg/mL
- Repeat ACTH
- Consider CRH test
ACTH > 20 pg/mL
ACTH-dependent Cushing’s
CUSHING’S DISEASE*
HDDST: high-dose dexamethasone suppression test (8 mg overnight); CT: computed tomography; MRI: magnetic resonance imaging; PMAH: primary 
macronodular adrenal hyperplasia; PPNAD: primary pigmented nodular adenocortical disease; BIPSS: bilateral and simultaneous petrosal sinus sampling; 
USG: ultrasound; PET-CT: positron emission tomography-computed tomography; * Even before the definition of Cushing’s disease or EAS, anatomical 
images of the neck/chest/abdomen/pelvis are commonly obtained to contribute to the identification of the ACTH-producing source. 
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False negatives can occur in approximately 5-10% 
of cases due to technical difficulties, anatomical varia-
tions such as plexiform presentation, unresponsiveness 
to secretagogues or use of drugs that modulate ACTH 
secretion. One study reported that false negatives only 
occurred in cases where the ACTH peak was lower than 
400 pg/mL (145). 
Fortunately, false positives are rare and can occur in 
cases of EAS during periods of normocortisolism (cy-
clical Cushing’s syndrome or use of medical therapy for 
Cushing’s) or in the rare case of ectopic CRH secretion 
(146). 
This procedure should therefore be carried out in 
the presence of endogenous active hypercortisolism. 
Consequently, it is necessary to collect 24-h UFC and/
or nocturnal salivary cortisol in the evening of the test 
or in the preceding days to validate the procedure. 
As it is an invasive procedure with potential side 
effects, the procedure should be performed in referral 
centers with highly skilled professionals. 
Fortunately, the rate of serious complications such as 
cerebral vascular injury, deep venous thrombosis, pul-
monary embolism, subarachnoid hemorrhage or cranial 
nerve paralysis has been very low or absent in many stu-
dies (147-150). The most common complications in-
clude bruising at the venipuncture site in 3-4% of the 
cases (147). Usually, a 5000 IU IV heparin infusion is 
recommended after the start of venous puncture (151). 
The procedure is performed under stimula-
tion of oCRH (145,152), hCRH or desmopressin 
(144,153,154) at the same doses as those used for dy-
namic secretion tests. Samples are taken at 0, 3, 5 and 
10 minutes after the stimulus, and the peak is usually 
3 to 5 min after stimulus. The central to peripheral 
ACTH ratio, or the “central gradient”, that is suggesti-
ve of CD etiology is defined as a ratio greater than 2 at 
baseline levels and/or higher than 3 at the peak. 
Lateralization is defined as an interpetrosal gradient 
higher than 1.4 (152). However, lateralization is surgi-
cally confirmed in only approximately 60-80% of cases 
(1,155-157). 
Furthermore, it is important to note that due to a 
high pretest probability of CD diagnosis, it is recom-
mended to consider the possibility of a false negative 
result in cases without a central ACTH gradient. 
Several aspects have to be observed during the pro-
cedure to ensure a reliable collection, including the 
following: successful catheterization, as confirmed by 
visualization of the intercavernous sinuses and contra-
lateral petrosal sinus after contrast infusion; observa-
tion of anomalies or asymmetries in the petrosal sinus 
drainage (123,146,158); and proper processing of the 
samples collected by storage in previously chilled plastic 
tubes with EDTA and immediate placement in an ice 
bath after collection. 
Finally, recent studies have verified the prolactin 
values in BIPSS that can be used to correct for pos-
sible false negative gradients (51,123,159,160). The 
values are initially obtained by calculating the central 
to peripheral prolactin gradient ipsilateral to the largest 
gradient of ACTH (baseline), which should be higher 
than 1.8. When the prolactin values are less than 1.8, an 
unreliable collection of the inferior petrosal sinus shou-
ld be considered. Subsequently, a ratio of the ACTH 
and ipsilateral prolactin gradients with cutoff values hi-
gher than 0.8 in one study (51) and higher than 1.3 in 
another (123) have been suggested as indicative of a 
CD diagnosis. 
Additionally, a recent study showed the utility of 
prolactin in improving tumor location by using the 
ratio of the interpetrosal gradient of ACTH and the 
interpetrosal gradient of prolactin (161). However, un-
like the evaluation of prolactin in BIPSS, the role of 
prolactin evaluation in improving tumor location is still 
in its infancy, and further studies are thus needed to 
support its use.
Desmopressin test
The desmopressin test has been used for the differen-
tial diagnosis of ACTH-dependent Cushing’s syndro-
me since 1993 (87). Subsequently, several studies have 
shown a response in the majority of patients with CD 
(~80%) (1). However, patients with EAS eventually also 
show a response, varying from 27-38% (1,116). 
Desmopressin acts on both the AVPR1B (V3 or 
V1b) (137,162,163) and the AVPR2 (V2) (162,164) 
vasopressin receptors, which have been documented to 
be overexpressed in corticotropic tumors when com-
pared to both normal pituitary tissue and tumors caus-
ing EAS (138,163,165,166). 
The test is performed in the same way as that used 
to differentiate between Cushing’s syndrome and pseu-
do-Cushing’s (10 µg IV). An increase in cortisol higher 
than 20% and in ACTH higher than 35% compared to 
baseline for both measures is considered predictive of 
CD, similar to the oCRH test in the differential diag-
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However, due to the frequently observed response 
in patients with EAS, the desmopressin test should not 
be routinely performed to differentiate between the 
diagnoses of CD and EAS and should therefore be re-
served to distinguish between Cushing’s syndrome and 
pseudo-Cushing’s or as a secretagogue in the BIPSS 
procedure. 
Other tests
Other laboratory findings may be helpful in establish-
ing a diagnosis of CD or EAS, although not conclusive-
ly: hypokalemia, present in 70% of EAS vs. 10% of CD 
patients due to cortisol mineralocorticoid activity in 
conditions of enzyme 11β-HSD2 saturation; extreme-
ly high plasma ACTH concentrations (> 400 to 500 
pg/mL; > 88 to 110 pmol/L) in EAS; positive tumor 
markers in EAS (examples: calcitonin, gastrin, chromo-
granin, βhCG, alpha-fetoprotein, CEA, CA 19-9, CA 
125) (1,167); and measurement of pro-opiomelano-
cortin (POMC) and/or ACTH precursors (168,169), 
which are commonly present in patients with EAS de-
spite the poor availability of these measures.
Diagnosis of EAS and search for ACTH-producing 
source
The diagnosis of EAS can be made by identifying the 
ACTH-producing source through surgical documen-
tation of the lesion with a positive immunohistoche-
mistry for ACTH, clinical and laboratory remission of 
Cushing’s syndrome after excision of the suspected le-
sion, or the absence of a center to peripheral ACTH 
gradient in a reliable BIPSS (not suggestive of a false 
negative result). 
An ectopic source of ACTH can be first recog-
nized by imaging studies (“overt”) or recognized 
in follow-up with repeated imaging methods (“co-
vert”), although it may also remain occult (8-27%) 
(115,116,134,170,171). 
The most common causes of EAS are intrathora-
cic (83%) (170), and bronchial/pulmonary carcinoid 
tumors are currently the most common etiologies 
(115,116,134,171). 
Thus, despite the stepwise diagnostic approach su-
ggested in this manuscript, thoracic and abdominal 
imaging (CT or MRI) are commonly performed, as an 
evident suspicious lesion may prevent the need for a 
BIPSS procedure in a patient without visible pituitary 
imaging in MRI. 
Finally, the search for a peripheral ACTH-producing 
source by imaging exams is indicated after a negative 
BIPSS for central gradient. The most common imag-
ing methods are ultrasonography (USG), CT and MRI. 
These should be requested for the thoracic region (CT 
or MRI), abdomen/pelvis (CT or MRI), and cervical 
region (USG). 
 Somatostatin receptor scintigraphy with Indium 
(111In-DTPA-octreotide, OctreoScan®) is an important 
functional complementary method (172), although 
its sensitivity is not higher than that of plain images 
(170,173,174), mainly due to the typically small size of 
bronchial carcinoid tumors (175). 
PET-FDG (18F 2-deoxy-D-glucose), a test often 
used in oncology, may eventually be requested to lo-
calize ACTH-secreting tumors. Although some case 
reports have shown its usefulness (176,177), larger de-
tailed studies have shown that it has no advantage over 
anatomical tests (170,178), probably due to the low 
metabolic activity of carcinoid tumors. 
New forms of PET such as 18F-DOPA-PET, scintig-
raphy with somatostatin analogues with new radionu-
clides such as Gallium (68Ga) (179,180), and improve-
ments in imaging techniques per se may increase the 
accuracy of functional imaging exams. 
Regarding the follow-up of patients with occult 
EAS with tumors that have not been localized, after 
proper treatment for hypercortisolism, they should 
be submitted at least once a year to new anatomical 
imaging of the cervical and thoracic/abdominal/pel-
vic regions, with special consideration to the chest, as a 
ACTH-producing source may appear many years after 
the onset of symptoms, with bronchial carcinoid being 
the most common cause (181).
Table 6 summarizes the methods for establishing a 
differential diagnosis of ACTH-dependent Cushing’s 
syndrome, and Figure 2 shows a flowchart of this diffe-
rential diagnosis approach.
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Table 6. Methods for the differential diagnosis of ACTH-dependent Cushing’s syndrome  





Sellar MRI (spin echo) - 50-60 - -
Ovine CRH test (% increase) (1,115,134) ACTH > 35% and Fs > 20% 86-93 92-94 -
Human CRH test (% increase) (85) ACTH > 105% and Fs > 14% 70 and 85 100 -
High-dose dexamethasone suppression test (8 mg overnight) (1) > 50% 65-100 65-100 -
High-dose dexamethasone suppression test (8 mg overnight) (140) > 80% 56 100 63
Bilateral and simultaneous petrosal sinus sampling (central to periphery ACTH gradient) 
(143,144)
Baseline ≥ 2 and/or peak ≥ 3 90-95 ~100 90-94
Other methods Comments
Desmopressin test (increase of ACTH > 35% and Fs > 20%) Low accuracy; should not be used routinely
K (hypokalemia) 70% EAS vs. 10% Cushing’s disease
Plasma ACTH Very high concentrations of ACTH (> 400-500 pg/mL) are suggestive of 
EAS
Tumor markers (calcitonin, gastrin, chromogranin, βhCG, alfa-fetoprotein, CEA, CA 19-9, 
CA125)
They can be measured (serum) or expressed (tissue) in up to 70% of EAS 
cases
POMC and/or ACTH precursors Not available; does not guide the etiologic diagnosis of EAS 
Fs: serum cortisol; EAS: ectopic ACTH syndrome; POMC: pro-opiomelanocortin.
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